EUVIMEDEUVIMED entdecken
Crossref

A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells

Xieqing Yang iD, Qiaoyun Zhang, Dongye Li, Lanxin Hu, Yu Wang, Xinyu Yan, Yunhua Li, Yong Wang, Fang Zhang, Jun Shen iD

Advanced Healthcare Materials · 2024-11 · 13 (29)

DOI: 10.1002/adhm.202401398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 02.10.2024. Verfasst von Xieqing Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Se…. Hauptthemen laut MEDLINE: Quinolines, Carcinoma, Hepatocellular, Neoplastic Stem Cells, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Chinese Postdoctoral Science Foundation, National Key R&D Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug resistance resulting from diverse mechanisms including the presence of cancer stem cells (CSCs) is the main obstacle for improving therapeutic efficacy of lenvatinib in hepatocellular carcinoma (HCC). Herein, a nanomedicine (siCD24‐Len‐MnO@PLAP) is developed by incorporating manganese oxide (MnO), lenvatinib (Len), and siRNA against CD24 (siCD24) into micelles composed of methoxypolyethylene glycol ( m PEG), poly‐L‐lysine (PLLys), and polyasparagyl(N‐(2‐Aminoethyl)piperidine) (PAsp(PIP)) triblock copolymer. The nanomedicine can respond to the tumor microenvironment (TME) to release lenvatinib, and produce Mn 2+ and O 2 , accompanied by changes in nanoparticle charge, which facilitates cellular endocytosis of siCD24‐loaded nanoparticles. The released siCD24 and lenvatinib synergistically reduces CD24 expression, resulting in a more pronounced inhibition of stemness of CSCs. In the mouse models of HCC using Huh7‐derived CSCs and Hepa1‐6‐derived CSCs, the nanomedicine shows remarkable anti‐cancer effect by enhancing the therapeutic effects of lenvatinib against HCC via reducing the expression level of CD24 and decreasing the expression of hypoxia inducible factor‐1α (HIF‐1α). Moreover, in situ production of paramagnetic Mn 2+ from the nanomedicine serves as an excellent contrast agent for magnetic resonance imaging (MRI) to monitor the therapeutic process. This study demonstrates that this multifunctional MRI‐visible siCD24‐ and lenvatinib‐loaded nanodrug holds great potential in enhancing therapeutic sensitivity for HCC lenvatinib therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesCarcinoma, HepatocellularNeoplastic Stem CellsLiver NeoplasmsPhenylurea CompoundsNanoparticlesAnimalsHumansCell Line, TumorMiceAntineoplastic AgentsCD24 AntigenMice, NudeMice, Inbred BALB CManganese CompoundsOxidesTumor MicroenvironmentRNA, Small InterferingMicelles

Stichwörter der Autor:innen

cancer stem cellshepatocellular carcinomalenvatinibmagnetic resonance imagingmicelle

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsAntineoplastic AgentsCD24 AntigenManganese CompoundsOxidesRNA, Small InterferingMicelles

Autor:innen und Institutionen

  • Department of Radiology, Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
  • College of Chemistry and Materials Science, Jinan University, No.855 Xingye Road East, Guangzhou, Guangdong, 510632, China.

ORCID-Profile: Xieqing Yang, Jun Shen

Förderung

  • Chinese Postdoctoral Science Foundation
  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Guangdong Basic Research Center of Excellence for Functional Molecular Engineering
  • National Key Research and Development Program of China

Zitieren

APA

Yang, X., Zhang, Q., Li, D., Hu, L., Wang, Y., Yan, X., Li, Y., Wang, Y., Zhang, F., & Shen, J. (2024). A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells. Advanced Healthcare Materials, 13(29). https://doi.org/10.1002/adhm.202401398

Vancouver

Yang X, Zhang Q, Li D, Hu L, Wang Y, Yan X, et al. A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells. Advanced Healthcare Materials. 2024;13(29). doi:10.1002/adhm.202401398

BibTeX
@article{Yang2024,
  author = {Yang, Xieqing and Zhang, Qiaoyun and Li, Dongye and Hu, Lanxin and Wang, Yu and Yan, Xinyu and Li, Yunhua and Wang, Yong and Zhang, Fang and Shen, Jun},
  title = {A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {29},
  doi = {10.1002/adhm.202401398}
}
Kostenlos starten →